P1/2, N=49, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Sep 2025 --> Sep 2026

Combination therapy with PD-1 blockade further promotes long-term immunological memory formation by activation of dendritic cells and reprogramming of the tumor microenvironment. These findings highlight the translational potential of DARPin-DC and its promising prospects for clinical combination with immunotherapies in the treatment of solid tumors, including refractory pancreatic cancer.

Our findings confirm that UrC has the potential to be treated by ADC. Trop2 has the highest high expression rate in UrC and is associated with a worse prognosis, which may be a potential target for ADC therapy for UrC.

In TNBC, ADCs such as sacituzumab govitecan and trastuzumab deruxtecan have improved progression-free survival in advanced cases. While ADCs have significantly advanced treatment options in TNBC, PDAC remains a difficult target due to its stroma-rich microenvironment and lack of high-density, tumor-specific antigens. This article emphasizes the need for tailor-made ADC designs to enhance results in various types of cancers and provides valuable insight into future advancements in precision oncology.

We investigated the effects of sMSLN on anetumab, an antibody-based therapy against MSLN, anetumab ravtansine, an antibody drug conjugate, and mechanisms to decrease sMSLN...Overall, sMSLN could represent a predictive biomarker for MSLN directed therapies. TPE may be more reliable than PIs to reduce sMSLN and ultimately restore sensitivity to these therapies in patients with high sMSLN.

P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2025 --> Jan 2026

P1, N=365, Recruiting, Seagen Inc. | Trial completion date: Nov 2028 --> Feb 2029 | Trial primary completion date: Nov 2028 --> Feb 2028

P1/2, N=200, Recruiting, RemeGen Co., Ltd. | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2024 --> Nov 2025

P1, N=81, Active, not recruiting, RemeGen Co., Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025

Our study stopped at interim analysis highlighting the benefit of PB in prrHGOC as standard of care.

The optimal anti-MSLN×4-1BB bsAb HK013-G1 exhibited synergistic antitumour effects by inducing an ADCC effect (innate immunity) and stimulating the 4-1BB signaling pathway (adaptive immunity) upon cross-bridging with MSLN with no systemic toxicity, which may offer the promise of an improved therapeutic window relative to that of 4-1BB agonists.